2.4.0.84142 - Disclosure - Acquisitions, License and Research Agreements (Details 3)truefalseIn Millions, unless otherwise specifiedfalse1false USDtruefalse$I2011Q3_IntellectNeurosciencesIncMemberhttp://www.sec.gov/CIK0000946840instant2011-09-30T00:00:000001-01-01T00:00:00falsefalseIntellect Neurosciences Inc.us-gaap_CounterpartyNameAxisxbrldihttp://xbrl.org/2006/xbrldivphm_IntellectNeurosciencesIncMemberus-gaap_CounterpartyNameAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$2false USDtruefalse$D2013Q2YTD_IntellectNeurosciencesIncMember_MaximumMemberhttp://www.sec.gov/CIK0000946840duration2013-01-01T00:00:002013-06-30T00:00:00falsefalseIntellect Neurosciences Inc.us-gaap_CounterpartyNameAxisxbrldihttp://xbrl.org/2006/xbrldivphm_IntellectNeurosciencesIncMemberus-gaap_CounterpartyNameAxisexplicitMemberfalsefalseMaximumus-gaap_RangeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_MaximumMemberus-gaap_RangeAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$3false USDtruefalse$D2013Q2YTD_HalozymeTherapeuticsMemberhttp://www.sec.gov/CIK0000946840duration2013-01-01T00:00:002013-06-30T00:00:00falsefalseHalozyme Therapeuticsus-gaap_CounterpartyNameAxisxbrldihttp://xbrl.org/2006/xbrldivphm_HalozymeTherapeuticsMemberus-gaap_CounterpartyNameAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$4false USDtruefalse$D2011Q4_HalozymeTherapeuticsMember_CombinationHalozymeCinryzeProductMemberhttp://www.sec.gov/CIK0000946840duration2011-10-01T00:00:002011-12-31T00:00:00falsefalseHalozyme Therapeuticsus-gaap_CounterpartyNameAxisxbrldihttp://xbrl.org/2006/xbrldivphm_HalozymeTherapeuticsMemberus-gaap_CounterpartyNameAxisexplicitMemberfalsefalseCombination Halozyme and Cinryze Productus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisxbrldihttp://xbrl.org/2006/xbrldivphm_CombinationHalozymeCinryzeProductMemberus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$5false USDtruefalse$I2011Q2_M0531_HalozymeTherapeuticsMember_CombinationHalozymeCinryzeProductMemberhttp://www.sec.gov/CIK0000946840instant2011-05-31T00:00:000001-01-01T00:00:00falsefalseHalozyme Therapeuticsus-gaap_CounterpartyNameAxisxbrldihttp://xbrl.org/2006/xbrldivphm_HalozymeTherapeuticsMemberus-gaap_CounterpartyNameAxisexplicitMemberfalsefalseCombination Halozyme and Cinryze Productus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisxbrldihttp://xbrl.org/2006/xbrldivphm_CombinationHalozymeCinryzeProductMemberus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$6false truefalseD2013Q2YTD_HalozymeTherapeuticsMember_CombinationHalozymeCinryzeProductMember_MaximumMemberhttp://www.sec.gov/CIK0000946840duration2013-01-01T00:00:002013-06-30T00:00:00falsefalseHalozyme Therapeuticsus-gaap_CounterpartyNameAxisxbrldihttp://xbrl.org/2006/xbrldivphm_HalozymeTherapeuticsMemberus-gaap_CounterpartyNameAxisexplicitMemberfalsefalseCombination Halozyme and Cinryze Productus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisxbrldihttp://xbrl.org/2006/xbrldivphm_CombinationHalozymeCinryzeProductMemberus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisexplicitMemberfalsefalseMaximumus-gaap_RangeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_MaximumMemberus-gaap_RangeAxisexplicitMemberPureStandardhttp://www.xbrl.org/2003/instancepurexbrli07false USDtruefalse$D2013Q2YTD_HalozymeTherapeuticsMember_HereditaryAngioedemaHaeMember_MaximumMemberhttp://www.sec.gov/CIK0000946840duration2013-01-01T00:00:002013-06-30T00:00:00falsefalseHalozyme Therapeuticsus-gaap_CounterpartyNameAxisxbrldihttp://xbrl.org/2006/xbrldivphm_HalozymeTherapeuticsMemberus-gaap_CounterpartyNameAxisexplicitMemberfalsefalseHereditary Angioedema (HAE)us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisxbrldihttp://xbrl.org/2006/xbrldivphm_HereditaryAngioedemaHaeMemberus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisexplicitMemberfalsefalseMaximumus-gaap_RangeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_MaximumMemberus-gaap_RangeAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$8false truefalseD2013Q2YTD_HalozymeTherapeuticsMember_AdditionalIndicationsMemberhttp://www.sec.gov/CIK0000946840duration2013-01-01T00:00:002013-06-30T00:00:00falsefalseHalozyme Therapeuticsus-gaap_CounterpartyNameAxisxbrldihttp://xbrl.org/2006/xbrldivphm_HalozymeTherapeuticsMemberus-gaap_CounterpartyNameAxisexplicitMemberfalsefalseAdditional Indicationsus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisxbrldihttp://xbrl.org/2006/xbrldivphm_AdditionalIndicationsMemberus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisexplicitMemberItemStandardhttp://www.viropharma.com/20130630itemvphm09false USDtruefalse$D2013Q2YTD_HalozymeTherapeuticsMember_AdditionalIndicationsMember_MaximumMemberhttp://www.sec.gov/CIK0000946840duration2013-01-01T00:00:002013-06-30T00:00:00falsefalseHalozyme Therapeuticsus-gaap_CounterpartyNameAxisxbrldihttp://xbrl.org/2006/xbrldivphm_HalozymeTherapeuticsMemberus-gaap_CounterpartyNameAxisexplicitMemberfalsefalseAdditional Indicationsus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisxbrldihttp://xbrl.org/2006/xbrldivphm_AdditionalIndicationsMemberus-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsAxisexplicitMemberfalsefalseMaximumus-gaap_RangeAxisxbrldihttp://xbrl.org/2006/xbrldius-gaap_MaximumMemberus-gaap_RangeAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$10false USDtruefalse$D2012Q4_M1206_SanquinRestOfWorldMemberhttp://www.sec.gov/CIK0000946840duration2012-12-05T00:00:002012-12-06T00:00:00falsefalseSanquin Rest of World (ROW)us-gaap_CounterpartyNameAxisxbrldihttp://xbrl.org/2006/xbrldivphm_SanquinRestOfWorldMemberus-gaap_CounterpartyNameAxisexplicitMemberUSDStandardhttp://www.xbrl.org/2003/iso4217USDiso42170USDUSD$1true 3us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItemsus-gaap_truenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalsexbrli:stringItemTypestringfalse0License and research agreements disclosures2false 4vphm_UpFrontLicensingFeePaidvphm_falsedebitinstantfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1truefalsefalse65000006.5USD$falsetruefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5truefalsefalse90000009.0USD$falsetruefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRepresents the non-refundable Up-front licensing fee paid.No definition available.false2Up-front licensing fee paid3false 4vphm_AdditionalLicenseFeesPayableOnAchievementOfCertainMilestonesvphm_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2truefalsefalse120000000120falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7truefalsefalse4100000041falsefalsefalse8falsefalsefalse00falsefalsefalse9truefalsefalse3000000030falsefalsefalse10falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRepresents the additional amount payable to entity which provides license based upon defined events under the license agreement.No definition available.false2Additional license fees payable on the achievement of certain milestones4false 4vphm_AdditionalLicenseFeePaidOnAchievementOfDevelopmentMilestonevphm_falsecreditdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4truefalsefalse30000003falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRepresents the additional amount paid to entity which provides license based upon development events under the license agreement.No definition available.false2Additional license fee paid on achievement of development milestone5false 4vphm_NumberOfAdditionalMilestoneIndicationsvphm_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8truefalsefalse33falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalsexbrli:integerItemTypeintegerThe number of additional milestone indications.No definition available.false256Number of additional milestone indications6false 4vphm_LicenseMaintenanceCostAnnualvphm_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3truefalsefalse10000001falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10falsefalsefalse00falsefalsefalsexbrli:monetaryItemTypemonetaryRepresents the annual license maintenance cost.No definition available.false2License maintenance cost annual7false 4vphm_RoyaltyExpensePercentagevphm_falsenadurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsetruefalse00falsefalsefalse2falsetruefalse00falsefalsefalse3falsetruefalse00falsefalsefalse4falsetruefalse00falsefalsefalse5falsetruefalse00falsefalsefalse6truetruefalse0.100.10falsefalsefalse7falsetruefalse00falsefalsefalse8falsetruefalse00falsefalsefalse9falsetruefalse00falsefalsefalse10falsetruefalse00falsefalsefalsenum:percentItemTypepureThe percentage of net sales used to calculate royalty payments under a contractual arrangement.No definition available.false0Percentage of royalty on net sales8false 4vphm_PaymentRelatedToAmendmentvphm_falsedebitdurationfalsefalsefalsefalsefalsefalsefalsefalseterseLabel1falsefalsefalse00falsefalsefalse2falsefalsefalse00falsefalsefalse3falsefalsefalse00falsefalsefalse4falsefalsefalse00falsefalsefalse5falsefalsefalse00falsefalsefalse6falsefalsefalse00falsefalsefalse7falsefalsefalse00falsefalsefalse8falsefalsefalse00falsefalsefalse9falsefalsefalse00falsefalsefalse10truefalsefalse13000001.3USD$falsetruefalsexbrli:monetaryItemTypemonetaryRepresents the payment made in relation to amended agreement.No definition available.false2Payment made related to amended agreementfalseAcquisitions, License and Research Agreements (Details 3) (USD $)HundredThousandsUnKnownUnKnownUnKnowntruefalsefalseSheethttp://www.viropharma.com/role/DisclosureAcquisitionsLicenseAndResearchAgreementsDetails3108